Effects Of Glucophage XR On HS-C-reactive Protein And Insulin Resistance In Normal-Weight Type 2 Diabetes Patients

【Objective】To observe effects of glucophage XR on serum HS-C-reactive protein and insulin resistance in normal-weight newly diagnosed type 2 diabetes patients (T2DM), and to explore its safety and effectiveness in normal weight T2DM patients thus to provide some evidence of glucophage as the first-line treatment in this kind of patients, at the same time to explore the role of HSCRP in T2DM.【Subjects and Methods】A total of 40 T2DM patients were enrolled in the study. They are all newly diagnosed type 2 diabetic patients (diagnosed as T2DM within 6 months) in department of endocrinology in our hospital , including 20 males and 20 females, 17-80 years old, HbA1c 7.0%-10.0%. They have not taken any oral hypoglycemic agents before or have received treatment within 14 days but have not received any treatment within one month,. They were divided into two groups with 20 patients including 10 males and 10 females each. The drugs were Glucophage XR or Diamicron-release tablets for 16 weeks, respectively. The Glucophage XR group were devided into three subgroups according to BMI level (BMI 18.5 kg/m2-24 kg/m2 as normal weight, BMI 24kg/m2 - 28kg/m2 as overweight, BMI≥28kg/m2 as obesity).The initial dose of Glucophage XR was 1500mg / day, once a day with dinner, if FPG> 7.0mmol/L after 4 weeks, the daily dose increased to 2000mg / day (oral once daily with dinner). The other group took Diamicron-release tablets for 16 weeks, the initial dose was 60mg / day (oral, once daily, 15 mins before breakfast), if FPG> 7.0mmol/L after 4 weeks,, the daily dose should increase to 90mg / day. Serum HSHSCRP, FINS, FBG, waist circumference, hip circumference, height, weight, BMI, blood pressure, blood lipids were tested before and after treatment. HOMA-IR=FNS(mIU/L)×FBG(mmol/L)/ 22.5。 【Results】1. Glucophage XR decreased FINS(P=0.041),FBG(P=0.049),HSCRP(P=0.047),TG(P=0.032),TC(P=0.027),LDL-C(P=0.021) in normal weight T2DM patients after treatment with 16 weeks.2. Glucophage XR decreased FINS(P=0.009),FBG(P=0.042),HSCRP(P=0.049),TG(P=0.048) , TC ( P=0.017 ) , LDL-C(P=0.040) and BMI(P=0.007) in over-weight T2DM patients after treatment with 16 weeks.3. Glucophage XR decreased FINS(P=0.015),FBG(P=0.035),HSCRP(P=0.044),TG(P=0.049),TC(P=0.047),LDL-C(P=0.015) and BMI (P=0.025) in obese T2DM patients after treatment with 16 weeks.4. There were no significant difference in the rangeability of FINS,FBG,HSCRP and blood lipids in of the three subgroups of Glucophage XR (P>0.05).5. Diamicron-release tablets decreased FBG(P=0.045) and HSCRP(P=0.049) in T2DM patients after treatment with 16 weeks.6. The descent rangeability of FINS(P=0.011),HSCRP(P=0.044) ,TG(P=0.043),TC(P=0.042),LDL-C(P=0.048),BMI (P=0.006) were higher in Glucophage group than in Diamicron group.【Conclusions】1. The effects of Glucophage XR in normal weight T2DM patients are similar with overweight and obese T2DM patients with no adverse reactions, thus can be used as the first-line treatment in this kind of patients,.2. Glucophage XR may decrease HSCRP and isulin resistance level in normal weight T2DM patients..